Analystreport

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was downgraded by analysts at Mizuho from a "buy" rating to a "neutral" rating. They now have a $4.00 price target on t

Corvus Pharmaceuticals, Inc.  (CRVS) 
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corvuspharma.com